The pharma industry is ready to embrace low carbon pressurised Metered Dose Inhalers (pMDIs). However, collaboration is needed across the value chain to reach the finish line, and specialist CDMOs have a vital role to play.
At Bespak, we are working to spearhead the transition and accelerate the journey to a more sustainable future. In our latest article in PMPS we share how we are leveraging an unmatched understanding of the manufacturing requirements for low carbon pMDIs, investing in the necessary manufacturing capabilities, and vocalising industry needs to regulatory authorities.
